A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

← catalyst calendar

NCT04747431 · readout ≤ 743 d

Sponsored by Passage Bio, Inc. (industry) · PASG — their whole pipeline →.

Phase

Phase 1/2

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

30estimated

Sites

Countries

Australia, Brazil, Canada +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-09-14

actual

When the study began enrolling

Primary completion

Aug 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Aug 2031

estimated

The whole study's end, after follow-up

First posted

2021-02-10

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-15

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Frontotemporal Dementia
FTD
FTD-GRN
Dementia Frontotemporal
C9orf72

Intervention

Drug: PBFT02

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Treatment-Related AEs and SAEs

measured Up to 5 years (multiple visits)

Change in Nerve Conduction Velocity and Amplitude from Baseline on Nerve Conduction Studies

measured From baseline to 5 years (multiple visits)

Change in Cellular and Humoral Response Against the Vector and Transgene in Serum

measured From baseline to 5 years (multiple visits)

Permalink · PASG's whole pipeline · Catalyst calendar · Every registered study · What changed